<?xml version="1.0" encoding="utf-8" standalone="no"?>
<!DOCTYPE file
  SYSTEM 'wikixml.dtd'>
<file type="Article" date="2024-10-21T01:08:53Z" sourceCorpus="COVID-19" filename="67466645" title="Razi_Cov_Pars" url="https://en.wikipedia.org/wiki/Razi_Cov_Pars">
	<text>
		<segment id="id67466645">Razi Cov Pars () is a COVID-19 vaccine developed by the Iranian Razi Vaccine and Serum Research Institute Razi Cov Pars is a covid-19 vaccine based on recombinant protein, which is being produced by Razi Vaccine and Serum Research Institute, Iran. This vaccine is the first injectable-intranasal recombinant protein corona vaccine.It's the second Iranian COVID-19 vaccine reaching human trials and is currently in phase III of clinical research during which it's compared to the Sinopharm BIBP vaccine. 

Medical uses
It requires three doses given day 0 (intramuscular), day 21 (intramuscular) and day 51 (intranasal spray).

Pharmacology
Razi Cov Pars is a recombinant protein subunit vaccine containing the SARS-CoV-2 spike protein.

Manufacturing
It's planned to produce one million doses of the vaccine each month as of September 2021.

As of 25 November 2021, 5 millions doses have been delivered to the Iranian Ministry of Health.

History

Clinical trials


See also
* Pharmaceuticals in Iran
* COVID-19 pandemic in Iran
* COVID-19 vaccine clinical research

References


Further reading

* 
* 
* 












</segment>
	</text>
</file>
